Shares of Impax Laboratories Inc. (NASDAQ:IPXL) were up 5.1% during mid-day trading on Monday . The company traded as high as $30.91 and last traded at $30.85, with a volume of 292,916 shares traded. The stock had previously closed at $29.35.

A number of analysts have recently issued reports on IPXL shares. Deutsche Bank AG lowered their price target on Impax Laboratories from $42.00 to $31.00 and set a “hold” rating on the stock in a research note on Wednesday, June 22nd. Goldman Sachs Group Inc. started coverage on Impax Laboratories in a research note on Monday, June 6th. They issued a “sell” rating and a $33.00 price target on the stock. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $41.00 price target on shares of Impax Laboratories in a research note on Friday, May 27th. Leerink Swann reaffirmed a “market perform” rating and issued a $33.00 price target (up from $31.00) on shares of Impax Laboratories in a research note on Wednesday, July 6th. Finally, Zacks Investment Research raised Impax Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 26th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $39.92.

The company has a market cap of $2.25 billion and a P/E ratio of 66.70. The firm has a 50-day moving average price of $31.49 and a 200-day moving average price of $33.91.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported $0.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.39 by $0.04. The company had revenue of $226 million for the quarter, compared to analysts’ expectations of $241.84 million. During the same period in the prior year, the company earned $0.09 earnings per share. The firm’s revenue was up 57.6% on a year-over-year basis. On average, equities research analysts forecast that Impax Laboratories Inc. will post $1.78 EPS for the current fiscal year.

A number of hedge funds recently bought and sold shares of IPXL. Neuberger Berman Group LLC increased its stake in Impax Laboratories by 0.7% in the fourth quarter. Neuberger Berman Group LLC now owns 55,998 shares of the specialty pharmaceutical company’s stock valued at $2,394,000 after buying an additional 366 shares in the last quarter. Nationwide Fund Advisors increased its stake in Impax Laboratories by 1.4% in the fourth quarter. Nationwide Fund Advisors now owns 57,674 shares of the specialty pharmaceutical company’s stock valued at $2,466,000 after buying an additional 793 shares in the last quarter. California State Teachers Retirement System increased its stake in Impax Laboratories by 1.5% in the fourth quarter. California State Teachers Retirement System now owns 132,825 shares of the specialty pharmaceutical company’s stock valued at $5,680,000 after buying an additional 1,971 shares in the last quarter. Engineers Gate Manager LP increased its stake in Impax Laboratories by 1,226.2% in the fourth quarter. Engineers Gate Manager LP now owns 90,940 shares of the specialty pharmaceutical company’s stock valued at $3,889,000 after buying an additional 84,083 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in Impax Laboratories by 8.4% in the fourth quarter. ProShare Advisors LLC now owns 71,272 shares of the specialty pharmaceutical company’s stock valued at $3,048,000 after buying an additional 5,531 shares in the last quarter.

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.